In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that ...

Vor Bio (VOR) presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy, ...

Today, as part of a national initiative funded by The John A. Hartford Foundation (JAHF), the national, independent nonprofit FAIR Health launched a new shared decision-making tool for Alzheimer's ...

Bailey Hutchins — a registered nurse who harnessed her two-year battle with Stage 4 colorectal cancer to inspire hundreds of ...